Public procurement notice: Contract Award Notice
Published: 2019-08-16
Buyer: Amgros I/S
Country: DK
Contract type: Supplies
Procedure: Open procedure
CPV classification: 33600000: Pharmaceutical products
Estimated value: 6720000 EUR
Award criteria: Lowest price

Technical requirements: Denmark, Norway and Iceland have entered into cooperation regarding the procurement of pharmaceuticals. The countries will jointly procure and award framework agreements in order to ensure the supply of pharmaceuticals to the public hospitals and health authorities in the countries. In Denmark certain pharmaceuticals is resold to the Faroe Island and Greenland. For this procurement group delivery to Iceland is an option, see Section II.2.11).
Tenders for the pharmaceuticals are invited so that the contracting authorities can enter into framework agreements for delivery of the pharmaceuticals requested in the list of products and specified under the various lots below (Section II.2.4).
The framework agreements are non-exclusive to the supplier. The hospitals and health authorities are not obliged to use the Framework agreement.
The above pharmaceuticals are put up for tender independently of the pharmaceuticals under the other procurement numbers.
Each procurement number is considered a separate lot. A supplier may thus choose to submit tender for one, several or all procurement numbers, and award will take place separately for each individual procurement number. Reference is made to the tender specifications, including the provisions on submission of tender under the individual procurement numbers.
Under the title ‘quantity in units’, an estimated consumption of the pharmaceuticals is indicated for each of the countries.
It should be noted that this estimate is based on historic consumption data and that the suppliers must expect that the actual purchase under a framework agreement may differ significantly from the estimate. Reference is made to paragraph 3.6 of the tender specifications and clause 2 of the framework agreement.
The supplier must have authorisation to produce, import or receive pharmaceuticals for wholesale distribution within the EU/EEA.
Marketing authorisations applicable for Denmark, Norway and Iceland must be in place for the pharmaceuticals in sufficient time to ensure that the pharmaceuticals appear in Medicinpriser.dk (Denmark), ‘Farmalogg’ (Norway) and ‘Lyfjaverðskrá’ (Iceland) no later than 1.12.2019. The requirement regarding and ‘Lyfjaverðskrá’ (Iceland) only apply if Iceland is part of the framework agreement, see Section II.2.11).
Clause 1 of the framework agreement provides for an option for delivery in a pre-agreement period (i.e. before the purchase period begins) and an option for delivery in a post-agreement period (i.e. after the purchase period). The 2 options may be exercised on the terms and conditions stipulated in the framework agreement and in the tender specifications.
For this procurement group delivery to Iceland is an option. The supplier can choose to submit a tender for this option. If the supplier is awarded a framework agreement the framework agreement will cover delivery of the pharmaceuticals in all 3 countries for the purchase period.
If the supplier chooses not to give a tender for the delivery to Iceland the framework agreement will cover delivery of the pharmaceuticals in Denmark and Norway.
The above pharmaceuticals are put up for tender independently of the pharmaceuticals under the other procurement numbers.
Each procurement number is considered a separate lot. A supplier may thus choose to submit tender for one, several or all procurement numbers, and award will take place separately for each individual procurement number. Reference is made to the tender specifications, including the provisions on submission of tender under the individual procurement numbers.
Under the title ‘quantity in units’, an estimated consumption of the pharmaceuticals is indicated for each of the countries.


Winner: Fresenius Kabi
Award value: 6720000
Number of bids: 2